12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 ...

Sanofi says Toujeo offers a similar blood glucose reduction to Lantus, with the added bonus of fewer cases of confirmed hypoglycaemia in patients at night – however this benefit was only ...

Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French ...